Clarity Pharmaceuticals (ASX:CU6) said results from a phase 2 diagnostic imaging study in patients with known or suspected neuroendocrine tumors showed that lesion detection by copper-64-Sartate outperformed Gallium-68-Dotatate, according to a Thursday Australian bourse filing.
The trial assessed the performance of the firm's Sartate imaging product as a potential new method to diagnose and manage neuroendocrine tumors.
Copper-64-Sartate detected 393 to 488 lesions, while Gallium-68-Dotatate identified 186 to 265 lesions.
Out of all the lesions identified, 230 to 251 of them were deemed to be discordant between copper-64-Sartate and Gallium-68-Dotatate scans, with nearly 94% of these discordant lesions detected only on the copper-64-Sartate scans.
Copper-64-Sartate was deemed safe and well tolerated, the filing said. The firm will start the next steps to conduct a registrational phase three study of copper-64-Sartate in neuroendocrine tumors with the US Food and Drug Administration's guidance.
The company recruited 45 participants with gastroenteropancreatic neuroendocrine tumors across four sites in Australia, comparing the diagnostic performance of copper-64-Sartate positron emission tomography (PET) at an average of four hours and around 20 hours post-administration to Gallium-68-Dotatate PET.
The firm's shares rose nearly 3% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。